MX2024012083A - Formulaciones intraorales alcalinas - Google Patents
Formulaciones intraorales alcalinasInfo
- Publication number
- MX2024012083A MX2024012083A MX2024012083A MX2024012083A MX2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A
- Authority
- MX
- Mexico
- Prior art keywords
- nicotine
- intraoral
- formulations
- alkaline
- chemically bonded
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Tobacco Products (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2204804.5A GB2613211B (en) | 2022-04-01 | 2022-04-01 | Alkaline oral formulations |
| GBGB2208807.4A GB202208807D0 (en) | 2022-06-15 | 2022-06-15 | Alkaline intraoral formulations |
| PCT/EP2023/058713 WO2023187224A1 (en) | 2022-04-01 | 2023-04-03 | Alkaline intraoral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012083A true MX2024012083A (es) | 2025-01-09 |
Family
ID=86096079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012083A MX2024012083A (es) | 2022-04-01 | 2024-09-30 | Formulaciones intraorales alcalinas |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250228770A1 (https=) |
| EP (1) | EP4504146B1 (https=) |
| JP (1) | JP2025513763A (https=) |
| CN (1) | CN119136784A (https=) |
| CA (1) | CA3246977A1 (https=) |
| MX (1) | MX2024012083A (https=) |
| WO (1) | WO2023187224A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9848634B2 (en) * | 2009-06-30 | 2017-12-26 | Philip Morris Products S.A. | Smokeless tobacco product |
| CN101966165B (zh) * | 2009-07-14 | 2012-06-13 | 无锡健而乐医药科技有限公司 | 口腔吸收固体泡腾制剂 |
| SE535587C2 (sv) | 2011-03-29 | 2012-10-02 | Chill Of Sweden Ab | Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse |
| CN103284318B (zh) * | 2013-06-20 | 2015-03-11 | 中国烟草总公司山东省公司 | 一种舌下烟及其制备方法 |
| WO2015193379A1 (en) * | 2014-06-18 | 2015-12-23 | Swedish Match North Europe Ab | A tobacco or non-tobacco product comprising magnesium carbonate |
| CN107259635A (zh) * | 2017-06-16 | 2017-10-20 | 云南中烟工业有限责任公司 | 一种烟碱复合盐含化片及其制备方法 |
| GB201714412D0 (en) * | 2017-09-07 | 2017-10-25 | Emplicure Ab | Evaporation devices containing plant material |
| WO2019110073A1 (en) | 2017-12-08 | 2019-06-13 | Fertin Pharma A/S | Solid oral nicotine formulation |
| CA3085065C (en) * | 2017-12-08 | 2023-12-05 | Fertin Pharma A/S | Formulations providing high nicotine concentrations |
| JP2022519542A (ja) * | 2019-02-01 | 2022-03-24 | スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー | pH調整剤を含む経口用ニコチン製品 |
| US20210169123A1 (en) * | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Pouched products with enhanced flavor stability |
| GB202105305D0 (en) * | 2021-04-14 | 2021-05-26 | Zanoprima Lifesciences Ltd | Supported nicotine composition |
-
2023
- 2023-04-03 JP JP2024558188A patent/JP2025513763A/ja active Pending
- 2023-04-03 CN CN202380036213.7A patent/CN119136784A/zh active Pending
- 2023-04-03 WO PCT/EP2023/058713 patent/WO2023187224A1/en not_active Ceased
- 2023-04-03 CA CA3246977A patent/CA3246977A1/en active Pending
- 2023-04-03 EP EP23718622.6A patent/EP4504146B1/en active Active
- 2023-04-03 US US18/852,956 patent/US20250228770A1/en active Pending
-
2024
- 2024-09-30 MX MX2024012083A patent/MX2024012083A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023187224A1 (en) | 2023-10-05 |
| US20250228770A1 (en) | 2025-07-17 |
| EP4504146A1 (en) | 2025-02-12 |
| JP2025513763A (ja) | 2025-04-30 |
| EP4504146B1 (en) | 2025-12-17 |
| CN119136784A (zh) | 2024-12-13 |
| CA3246977A1 (en) | 2023-10-05 |
| EP4504146C0 (en) | 2025-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045517A (es) | Procedimiento para dejar de fumar | |
| ES2174073T3 (es) | Forma farmaceutica solida para uso oral. | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| AR113901A1 (es) | Uso tópico y entrega de microorganismos oxidantes de amoniaco | |
| HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
| ES2089260T3 (es) | Composicion topica que contiene lisinato de cetoprofeno. | |
| CR7152A (es) | Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. | |
| ES2194328T3 (es) | Sistema de higiene femenina y kit que usa un dispositivo interlabial absorbente. | |
| ES2106782T3 (es) | Uso de una composicion de fumado. | |
| AR054805A1 (es) | Composiciones topicas para el tratamiento de la piel | |
| AR011846A1 (es) | Una composicion farmaceutica, y el procedimiento para prepararla | |
| MX9702415A (es) | Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos. | |
| CY1107649T1 (el) | Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος | |
| PE20060594A1 (es) | Composicion farmaceutica que contiene un agonista de ppar | |
| CO2024012870A2 (es) | Tratamiento de neurofibromas cutáneos con mirdametinib | |
| AR047986A1 (es) | Composiciones de pelicula | |
| CL2012000169A1 (es) | Composicion farmaceutioca de jarabe que comprende omeprazol o una sal del mismo, un agente solubilizante, un agente basificante, o un tampon, un edulcorente, un aromatizante y un antooxidante; metodo de preparacion; kit que comprende a la formulacion. | |
| MX2024012083A (es) | Formulaciones intraorales alcalinas | |
| ECSP034617A (es) | Kit de repinotan | |
| MX2021011420A (es) | Lamina hemostatica portadora de trombina. | |
| MX2024012081A (es) | Formulaciones de nicotina | |
| DE50109650D1 (de) | Topische behandlung bei der mastalgie | |
| AR000504A1 (es) | Procedimiento para la producción de una solución acuosa biocida de acción prolongada basada en ionesperacéticos | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| AR027287A1 (es) | Gonadotrofina |